New EU Template for Clinical Trial Recruitment and Informed Consent: What Pharma Teams Need to Know
Decision brief
Answer first · skim in under a minute
The European Medicines Agency (EMA) has introduced a new harmonised template for participant recruitment and informed consent procedures in clinical trials. This article explains the key changes, their impact on pharmaceutical companies, and answers frequently asked questions.
The informed consent research template v2.0 now on EudraLex Volume 10 is the MedEthicsEU/CTAG attempt to harmonise EU Part II recruitment and consent wording under the Clinical Trials Regulation. Pharma operations teams have until 1 September 2026 to finish transitioning new submissions onto the updated form.
Contents9 sections
Key Takeaways
- Template v2.0 (January 2026) covers recruitment and informed consent procedures for CTR Chapter V / Annex I K and L.
- Published on EudraLex Volume 10; highly recommended for all new Part II submissions across EU/EEA Member States concerned.
- Transition period runs until full implementation on 1 September 2026; already authorised trials need not be reworked retrospectively.
- Sections allow MSC-specific national requirements—harmonisation is structural, not a single pan-EU consent text.
What is the informed consent research template v2.0?
MedEthicsEU and the EU Clinical Trials Coordination and Advisory Group (CTAG) adopted the Recruitment and informed consent procedure template v2.0 in January 2026 to comply with Regulation (EU) No 536/2014.
The PDF template states its content is mandatory for specifying recruitment and consent procedures for all clinical trials and is highly recommended for every Member State concerned. Protocol cross-references are allowed when items are already covered, including protocol version numbers.
Where do sponsors find the informed consent research template?
The European Commission hosts Part II application document templates under EudraLex Volume 10, Chapter I (Application and application documents).
Volume 10 lists companion Part II templates for compensation, investigator CV, declaration of interest, and site suitability alongside the informed consent and patient recruitment procedure template (PDF/Word). Using the published set reduces MSC back-and-forth on missing structural elements.
What changes for CTIS Part II operations teams?
v2.0 applies to new Part II submissions: initial applications, additional Member States, and Part II filings that complete an Article 11 submission. It is not a demand to reopen authorised dossiers solely to swap templates.
- Map decentralised consent elements (video, remote discussion) into the specified fields
- Document who obtains consent, prior clinical relationships, privacy setting, and companion rights
- Capture MSC-specific national add-ons inside the reserved national sections
- Align patient-facing language packs with MSC translation rules discussed at CTIS Info Day materials
How does literature frame consent quality risk?
Independent reviews indexed on PMC continue to show variability in how recruitment and consent information is explained to participants across jurisdictions. The EU template does not invent new ethical principles; it standardises the fields sponsors must complete so ethics committees compare like-with-like dossiers.
For BD and outsourcing diligence, ask CROs whether SOPs already embed v2.0 fields, CTIS upload naming, and MSC translation matrices before promising multi-country start-up timelines that assume the old free-form Part II packs.
What remains flexible after 1 September 2026?
After the transition deadline, expect MSCs to reject new Part II packs that still use obsolete structures. National ethics nuances remain. The template does not replace the CTR’s substantive consent requirements or local language mandates; it is a harmonised questionnaire for describing how those requirements are met.
Sponsors running platform trials, paediatric cohorts, or emergency research should pre-build v2.0 narratives for legally designated representatives, staggered consent, and re-consent after substantial modifications. Budget extra medical-writing cycles in Q3 2026 for MSC translation packs rather than discovering gaps during CTIS validation. Document version control carefully: the Volume 10 page notes v2.0 replaces the prior recruitment/consent template for new filings, so SOPs and eTMF naming conventions must retire outdated filenames to avoid mixed packs across Member States in the same multinational trial. Track MedEthicsEU updates monthly through go-live.
Related NovaPharma coverage
- EU draft merger guidelines capabilities treatment
- European cancer guidelines add Delcath liver therapy
- Notable oncology FDA approvals May 2026
Frequently Asked Questions
What is the new informed consent research template?
It is the Recruitment and informed consent procedure template v2.0, adopted by MedEthicsEU and CTAG in January 2026, published on EudraLex Volume 10 to harmonise Part II documentation under Regulation (EU) No 536/2014.
When must sponsors use the informed consent research template v2.0?
EudraLex Volume 10 highly recommends using v2.0 from publication for new Part II submissions (initial, additional Member State, or Article 11 completion). A transition period accepts the prior version until full implementation on 1 September 2026; retrospective rework of already authorised trials is not required.
Does the informed consent research template replace national ethics rules?
No. Each template section allows Member State–specific legislative requirements. Sponsors must still meet national ethics and language rules while using the harmonised structure for recruitment and consent procedures.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
